ID   RD.TG6
AC   CVCL_DP30
SY   RD-TG.6
DR   cancercelllines; CVCL_DP30
DR   Wikidata; Q54949552
RX   PubMed=7707048;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pelvis, muscle; UBERON=UBERON_0001325.
DI   NCIt; C8971; Embryonal rhabdomyosarcoma
DI   ORDO; Orphanet_99757; Embryonal rhabdomyosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1649 ! RD
SX   Female
AG   7Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 13
//
RX   PubMed=7707048; DOI=10.1002/neu.480260212;
RA   McLaurin J., Trudel G.C., Shaw I.T., Antel J.P., Cashman N.R.;
RT   "A human glial hybrid cell line differentially expressing genes
RT   subserving oligodendrocyte and astrocyte phenotype.";
RL   J. Neurobiol. 26:283-293(1995).
//